Clik here to view.
The drug to improve sexual POTENCY “LEVITRA”
Levitra (Vardenafil) is only drug of class PDE-5, which demonstrated in clinical studies increasing the duration of erection for more than 2 times. Currently, lasting erections is a new criterion for...
View ArticleClik here to view.
Levitra from Bayer
Vardenafil, the drug used for the treatment of impotence has the brand name Levitra. It is a creation of a German company Bayer AG known for the production of chemicals and pharmaceuticals. This...
View ArticleClik here to view.
Erectile dysfunction and its types
According to statistics almost every person over 20 years has symptoms of erectile dysfunction: lack of rigidity of the penis in an excited state and therefore the absence of complete sexual...
View ArticleClik here to view.
What should I do if I take an overdose of Levitra?
There are data on several episodes of taking Levitra 80 mg per day, which were not accompanied by the development of severe adverse reactions. At the same time, when it is used at a dose of 40 mg twice...
View ArticleClik here to view.
Possible side effects of Levitra
Levitra is usually well tolerated. Side effects are usually slightly to moderately expressed and are transient. The most common side effects are (1-10%): Headaches; Hot flashes; Dyspepsia; Nausea;...
View ArticleClik here to view.
Levitra with other drugs
Consult with your doctor , if you take the next drug: • imatinib (Gleevec); • conivaptan (Vaprisol); • nefazodone (an antidepressant); • isoniazid (for treating tuberculosis); • antifungal...
View ArticleClik here to view.
Levitra with other drugs
Do not takethis drug with similar drugs,for example tadalafil/sildenafil (Cialis/Viagra). Before taking it, tell your urologist about all other drugs you use: imatinib (Gleevec);...
View ArticleClik here to view.
ED risk factors
Amongst diabetic men there are additional ED risk factors such as: Overweight Smoking habits Too few sport exercise Other lifestyle factors. Surgery or injury can damage nerves and arteries going to...
View Article
